BioCentury
ARTICLE | Clinical News

Alexo reports preliminary Phase I data for ALX148 in solid tumors and lymphoma

December 8, 2017 8:58 PM UTC

In November, Alexo Therapeutics Ltd. (Dublin, Ireland) reported preliminary data from 17 patients with advanced solid tumors and lymphoma in a Phase I trial showing that IV ALX148 was well tolerated with 1 treatment-related serious adverse event of neutropenia plus infection. Most treatment-related adverse events were Grade 1 or 2. Data were presented at the Society for Immunotherapy of Cancer meeting in National Harbor, Md.

The open-label, U.S. trial's first part is evaluating 0.3-30 mg/kg doses of ALX148 given weekly or every two weeks. The second part will evaluate ALX148 in combination with Keytruda pembrolizumab, Herceptin trastuzumab or Rituxan rituximab. The trial's primary endpoint is evaluating safety...

BCIQ Company Profiles

Iratel Ventures

BCIQ Target Profiles

CD47